 Acetamides
"Acetamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
| Descriptor ID |
D000081
|
| MeSH Number(s) |
D02.065.064 D02.241.081.018.110
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Acetamides".
Below are MeSH descriptors whose meaning is more specific than "Acetamides".
This graph shows the total number of publications written about "Acetamides" by people in this website by year, and whether "Acetamides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 2 | 3 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Acetamides" by people in Profiles.
-
Fong SL, Utidjian L, Kaur M, Abend NS, Wainwright MS, Grande KM, Foskett N, Roebling R, Guerriero RM, Jain B, Rao S, Stoltenberg M, Williams P, Yuen N, Dickinson K, McDonald J, Maltenfort M, Forrest CB. Safety of intravenous lacosamide in hospitalized children and neonates. Epilepsia. 2023 09; 64(9):2297-2309.
-
Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022 08; 87(2):373-374.e5.
-
Drouin G, Droz B, Leresche F, Payraudeau S, Masbou J, Imfeld G. Direct and indirect photodegradation of atrazine and S-metolachlor in agriculturally impacted surface water and associated C and N isotope fractionation. Environ Sci Process Impacts. 2021 Nov 17; 23(11):1791-1802.
-
Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep. 2020 10 13; 43(10).
-
Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, McLennan G, Fassler R, Reichmann D, Karni R, Preisinger C, Wilhelm T, Huber M, Tirosh B. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun. 2020 03 11; 11(1):1304.
-
Guttman-Yassky E, Hanifin JM, Boguniewicz M, Wollenberg A, Bissonnette R, Purohit V, Kilty I, Tallman AM, Zielinski MA. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019 01; 28(1):3-10.
-
Wrenbeck EE, Azouz LR, Whitehead TA. Single-mutation fitness landscapes for an enzyme on multiple substrates reveal specificity is globally encoded. Nat Commun. 2017 06 06; 8:15695.
-
Meador KJ, Loring DW, Boyd A, Echauz J, LaRoche S, Velez-Ruiz N, Korb P, Byrnes W, Dilley D, Borghs S, De Backer M, Story T, Dedeken P, Webster E. Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine. Epilepsy Behav. 2016 09; 62:267-75.
-
Chua-Tuan JL, Cao D, Iwanicki JL, Hoyte CO. Cardiac sodium channel blockade after an intentional ingestion of lacosamide, cyclobenzaprine, and levetiracetam: Case report. Clin Toxicol (Phila). 2015 Jul; 53(6):565-8.
-
Takahashi H, Riether D, Bartolozzi A, Bosanac T, Berger V, Binetti R, Broadwater J, Chen Z, Crux R, De Lombaert S, Dave R, Dines JA, Fadra-Khan T, Flegg A, Garrigou M, Hao MH, Huber J, Hutzler JM, Kerr S, Kotey A, Liu W, Lo HY, Loke PL, Mahaney PE, Morwick TM, Napier S, Olague A, Pack E, Padyana AK, Thomson DS, Tye H, Wu L, Zindell RM, Abeywardane A, Simpson T. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915). J Med Chem. 2015 Feb 26; 58(4):1669-90.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|